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Abstract
Aims/hypothesis Reductions in peroxisome proliferator-
activated receptor gamma, coactivator 1 alpha (PGC-1α)
levels have been associated with the skeletal muscle insulin
resistance. However, in vivo, the therapeutic potential of
PGC-1α has met with failure, as supra-physiological
overexpression of PGC-1α induced insulin resistance, due
to fatty acid translocase (FAT)-mediated lipid accumulation.
Based on physiological and metabolic considerations, we
hypothesised that a modest increase in PGC-1α levels would
limit FAT upregulation and improve lipid metabolism and
insulin sensitivity, although these effects may differ in lean
and insulin-resistant muscle.
Methods Pgc-1α was transfected into lean and obese Zucker
rat muscles. Two weeks later we examined mitochondrial
biogenesis, intramuscular lipids (triacylglycerol, diacylgly-
cerol, ceramide), GLUT4 and FAT levels, insulin-stimulated
glucose transport and signalling protein phosphorylation
(thymoma viral proto-oncogene 2 [Akt2], Akt substrate of
160 kDa [AS160]), and fatty acid oxidation in subsarcolem-
mal and intermyofibrillar mitochondria.
Results Electrotransfection yielded physiologically relevant
increases in Pgc-1α (also known as Ppargc1a) mRNA and
protein (∼25%) in lean and obese muscle. This induced mito-
chondrial biogenesis, and increased FAT and GLUT4 levels,
insulin-stimulated glucose transport, and Akt2 and AS160
phosphorylation in lean and obese animals, while bioactive
intramuscular lipids were only reduced in obese muscle.
Concurrently, PGC-1α increased palmitate oxidation in sub-
sarcolemmal, but not in intermyofibrillar mitochondria, in both
groups. In obese compared with lean animals, the PGC-1α-
induced improvement in insulin-stimulated glucose transport
was smaller, but intramuscular lipid reduction was greater.
Conclusions/interpretations Increases in PGC-1α levels,
similar to those that can be induced by physiological
stimuli, altered intramuscular lipids and improved fatty acid
oxidation, insulin signalling and insulin-stimulated glucose
transport, albeit to different extents in lean and insulin-
resistant muscle. These positive effects are probably
attributable to limiting the PGC-1α-induced increase in
FAT, thereby preventing bioactive lipid accumulation as has
occurred in transgenic PGC-1α animals.
Keywords Akt2 . AS160 . Ceramide . Diacylglycerol .
FAT. Fatty acid oxidation . GLUT4 .Mitochondria .
Muscle fibres . Triacylglycerol
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AS160 Akt substrate of 160 kDa
COXIV Cytochrome c oxidase subunit IV
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FABP Fatty acid binding protein
FAT Fatty acid translocase
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gamma, coactivator 1 alpha





Insulin resistance is a key feature of type 2 diabetes.
The accumulation of lipids within skeletal muscle has
been associated with the development of insulin
resistance, as excess intramuscular lipid metabolites
interfere with insulin signalling, leading to impaired
removal of glucose from the circulation [1]. Increasing
fatty acid oxidation while reducing intramuscular lipids is
thought to be an effective means to improve insulin
sensitivity, as has been shown with genetic studies and
with exercise [2–4].
The peroxisome proliferator-activated receptor γ co-
activator 1 alpha (PGC-1α) has been implicated in the
regulation of skeletal muscle oxidative metabolism and
mitochondrial biogenesis [5]. In muscle cell lines, increased
levels of PGC-1α induced insulin-sensitising effects via
the upregulation of selected genes involved in fatty acid
β-oxidation, glucose transport and oxidative phosphory-
lation [6, 7], while in type 2 diabetes, muscle PGC-1α
expression was reduced [8, 9]. Collectively, these studies
suggest that PGC-1α may be a key factor regulating
insulin sensitivity in mammalian muscle [5–9]. However,
experimental studies in vivo have been disappointing.
Transgenic Pgc-1α (also known as Ppargc1a) overexpres-
sion yielded an insulin-resistant phenotype [10, 11], calling
into question the therapeutic potential of PGC-1α. Alter-
natively, a model of transgenic Pgc-1α overexpression
may have obscured the positive metabolic effects of this
co-activator.
In transgenic animals, Pgc-1α mRNA overexpression is
very large (6- to 21-fold increase) [10–12], well beyond
that which occurs physiologically [13]. Excessive PGC-1α
production induces many undesirable consequences, in-
cluding abnormal mitochondrial proliferation, disruption of
myofibrillar architecture, displacement of nuclei [12],
obesity, intramuscular lipid accumulation and insulin
resistance [10, 11]. We [3, 13] have suggested that insulin
resistance in PGC-1α transgenic mice [10, 11] may stem
from a large, PGC-1α-induced increase in the fatty acid
transporter, fatty acid translocase (FAT), which has been
associated with increases in intramuscular lipids and insulin
resistance in humans and in animals [14, 15]. Viewed in
this light, PGC-1α-induced insulin resistance in transgenic
mice is less of a paradox than has been suggested [11].
Recently, we showed that inducing a modest increase in
PGC-1α protein, based on physiological and metabolic
considerations, has an insulin-sensitising effect in healthy
muscle [3]. Nevertheless, some very critical questions
remain unanswered, e.g.: (1) whether modest PGC-1α
overproduction also improves insulin action in severely
insulin-resistant muscle; and (2) whether PGC-1α-induced
metabolic effects are similar in lean and insulin-resistant
muscle.
Skeletal muscle insulin resistance can be examined in a
model of high fat feeding [4] or in a genetically predisposed
model such as obese Zucker rats [14]. Since insulin
resistance is much greater in obese Zucker rats, we selected
this more severe model to ascertain whether PGC-1α
overproduction within physiological limits increased mito-
chondrial biogenesis, and improved mitochondrial fatty
acid oxidation and insulin-stimulated glucose transport and
signalling. In addition, we determined whether PGC-1α
induced similar effects in healthy and insulin-resistant
muscles. We hypothesised that modest PGC-1α overpro-




The following were purchased: [1-14C]palmitate and 3-O-
methyl-[3H]glucose (GEHealth Care, Oakville, ON, Canada);
insulin (Humulin-R; Eli-Lilly, Toronto, ON, Canada); and the
following antibodies: PGC-1α (VWR Canlab, Mississauga,
ON, Canada); thymoma viral proto-oncogene 2 (Akt2), anti-
IRS-1, anti-AMP-activated protein kinase (AMPK)α2, anti-
phosphatidylinositol 3 (PI3)-kinase (Upstate, Lake Placid,
NY, USA); anti-Akt phosphos473, anti-Akt phosphothr308,
anti-Akt substrate of 160 kDa (AS160; Cell Signalling,
Danvers, MA, USA); anti-Akt substrate of 160 kDa (AS160)
phosphothr642 (Medicorp, Montreal, QC, Canada); anti-
GLUT4 (Chemicon, Temecula, CA, USA); anti-cytochrome
c oxidase subunit IV (COXIV; Molecular Probes, Eugene,
OR, USA); and goat anti-rabbit and goat anti-mouse (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). The mono-
clonal antibody MO25 [14] was used to detect FAT. All other
reagents were obtained from Sigma-Aldrich (St Louis,
MO, USA).
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Animals
Age-matched, 7-week-old, male lean (180–200 g) and
obese (350 g) Zucker rats (Charles River, Baie d’Urfé,
QC, Canada) were housed in controlled facilities (temper-
ature 20°C, 40% humidity, 12 h light–dark cycle) with
free access to water and chow. Principles of laboratory
animal care (National Institutes of Health publication no.
85-23, revised 1985; http://grants1.nih.gov/grants/olaw/
references/phspol.htm) were followed, as well those of
the Canadian Council on Animal Care. All procedures
were approved by the University of Guelph Animal Care
Committee.
Descriptive characteristics of lean and obese Zucker rats
Glucose, fatty acids and insulin Glucose was determined
using the glucose oxidase method (Beckman glucose
analyser; Beckman Coulter Canada Inc., Mississauga, ON,
Canada). Commercial kits were used for fatty acids (Wako
Diagnostics, Richmond, VA, USA) and insulin (Millipore,
Danvers, MA, USA).
Tissue removal and muscle fibre composition Rats were
anaesthetised with Somnotol (6 mg/100 g body weight, i.p.).
Metabolically heterogeneous muscles (extensor digitorum
longus [EDL], red tibialis anterior, white tibialis anterior
[TA], plantaris [PL], soleus, red gastrocnemius and white
gastrocnemius [WG]) were excised, freeze clamped
(liquid nitrogen) and stored at −80°C until analysed.
Muscle fibre composition of muscles in lean and obese
animals was determined as described by us recently [3],
by staining serial cross sections (10 µm) for myofibrillar
ATPase and succinate dehydrogenase, from which we
determined their physiological and metabolic characteristics
[3].
Transfecting muscle with Pgc-1α The Pgc-1α expression
construct (gift from B. Spiegelman, Harvard University,
Boston, MA, USA) was produced by subcloning the Pgc-
1α coding sequence into a mammalian expression vector
(pcDNA 3.0; Invitrogen, Burlington, ON, Canada). The
pcDNA3.0 vector was used for control experiments
(Invitrogen, Burlington, ON, Canada). Pgc-1α-pcDNA
and pcDNA3.0 plasmid stocks for electroporation were
produced by large-scale plasmid isolation from transformed
Escherichia coli cells (One-Shot; Invitrogen, San Diego,
CA, USA) using commercially available kits (GIGA-prep
kits; Invitrogen, Burlington, ON, Canada).
Electrotransfection of tibialis anterior muscle was per-
formed as previously described in detail [3, 16, 17]. Briefly,
animals were anaesthetised with isoflurane and the lower
hindlimbs were shaved and sterilised (iodine and 70% ethanol
[vol./vol.]). To increase transfection efficiency [18–20],
hyaluronidase (100 µl, i.e. 0.15 U/μl in 50% [vol./vol.]
saline) was injected through the skin and into the TA muscle.
After 2 h, TA muscles were then either electrotransfected
with Pgc-1α-pcDNA plasmid (500 μg Pgc-1α in 50% [vol./
vol.] saline) or with empty pcDNA3.0 plasmid (500 μg
pcDNA in 50% [vol./vol.] saline). Electroporation of the
intact TA muscle was performed as previously reported by
us [3, 16, 17, 21] using plate electrodes and nine electric
pulses (electric field 180 V/cm, 1 Hz, 20 ms in duration;
ECM 830 Square Wave Electroporator; BTX, San Diego,
CA, USA). Animals were then provided with an analgesic
(Temgesic) and allowed to recover for 2 weeks after
transfection. This protocol results in transfection of 30% of
the muscle fibres (data not shown). Transfection with higher
voltages can improve transfection efficiency, but causes
muscle damage (C. R. Benton and A. Bonen, unpublished
observations; [20]).
Mitochondrial DNA, Pgc-1α mRNA, western blotting
and enzyme activities
Mitochondrial DNA Mitochondrial DNA content was deter-
mined using real-time PCR, as described previously [3].
Total DNA was isolated using a kit (DNeasy Blood and
Tissue Kit; Qiagen Inc. Canada, Burlington, ON, Canada).
Real-time PCR was performed (7500 Real-Time PCR
System; Applied Biosystems Canada, Streetsville, ON,
Canada) using Platinum SYBR Green qPCR Supermix-
UDG (Invitrogen). mtDNA primers were designed using
the rat mitochondrial genome sequence (Genbank accession
number NC_001665) within the NADH dehydrogenase
subunit 5 gene: forward 5′-GCAGCCACAGGAAAAT
CCG-3′; reverse 5′-GTAGGGCAGAGACGGGAGTTG-3′.
Primers measuring genomic content were designed within
the solute carrier family 16, member1 gene sequence on
chromosome 2 (Genbank accession number NC_005101):
forward 5′-TAGCTGGATCCCTGATGCGA-3′; reverse 5′-
GCATCAGACTTCCCAGCTTCC-3′. mtDNA content was
calculated by theΔΔCt method using genomic DNA content
as an internal standard with 7500 System SDS Software
(version 1.2.1.22; Applied Biosystems Canada, Streetsville,
ON, Canada).
Pgc-1α mRNA This was determined as we have described
previously [3]. Total RNAwas isolated from muscle using a
combination of Trizol reagent (Invitrogen, Burlington, ON,
Canada) and a kit (RNeasy Mini Kit; Qiagen Inc., Canada,
Burlington, ON, Canada). Reverse transcription was carried
out using a kit (First Strand cDNA Synthesis Kit for RT-
PCR [AMV]; Roche, Mississauga, ON, Canada) using
random primers. Real-Time PCR was performed using
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7500 Real-Time PCR System (Applied Biosystems) using
Platinum SYBR Green qPCR Supermix-UDG (Invitrogen).
Relative Pgc-1α mRNA levels were calculated using the
ΔΔCt method using 7500 System SDS Software Version
1.2.1.22 (Applied Biosystems Canada, Streetsville, ON,
Canada). 18S ribosomal RNA was used as an endogenous
control. The following primer sets were used: Pgc-1α
forward 5′-CGATGACCCTCCTCACACCA-3′, Pgc-1α
reverse 5′-TTGGCTTGAGCATGTTGCG-3′; 18S forward
5′-GTTGGTTTTCGGAACTGAGGC-3′, 18S reverse
5′-GTCGGCATCGTTTATGGTCG-3′.
Protein isolation, activity and western blotting Muscles
were homogenised and proteins separated using SDS-
PAGE as previously described [3, 14]. Equal quantities of
protein were loaded for control and transfected muscles
(confirmed with Ponceau S staining). Signals were detected
using enhanced chemiluminescence (Perkin Elmer Life
Science, Boston, MA, USA) and quantified by densitometry
(SynGene, ChemiGenius2; Perkin-Elmer, Woodbridge, ON,
Canada). Citrate synthase activity was measured in muscle
homogenate [14].
Basal and insulin-stimulated glucose transport, and Akt
and AS160 phosphorylation
Basal and insulin-stimulated glucose transport We deter-
mined 3-O-methyl-[3H]glucose transport under basal con-
ditions and during a euglycaemic–hyperinsulinaemic clamp
of perfused tibialis anterior muscles (18 ml/min, 95% O2/
5% CO2 Krebs–Henseleit buffer, 2 mmol/l pyruvate, 4%
BSA [wt/vol.]) as described previously [3]. After 30 min,
control and transfected muscles were excised, blotted dry,
digested and radioactivity counted. 3-O-Methyl-[3H]glucose
transport rates were determined using standard calculations.
Insulin-stimulated phosphorylation of Akt and AS160
Phosphorylation of Akt (thr308, ser473) and AS160
(thr642) was determined in control and PGC-1α-transfected
muscles under basal conditions (saline injection, i.p.) and
after injecting insulin (20 U/rat i.p. 10 min) [3]. Thereafter,
muscles were frozen and stored (−80°C).
Intramuscular lipids and mitochondrial fatty acid oxidation
Intramuscular lipids Control and transfected muscles were
analysed for triacylglycerol, diacylglycerol and ceramide
content as reported previously [22, 23]. Briefly, lipids were
extracted with a modified Folch procedure and thin-layer
chromatography was used to separate lipids. Separated
lipids were methylated and fatty acid methyl esters were
extracted. Samples were analysed by gas–liquid chroma-
tography (5890 Series II; Hewlett-Packard, Houston, TX,
USA) and flame-ionisation detector (Agilent Technologies,
Santa Clara, CA, USA).
Mitochondrial isolation and oxidation To obtain sufficient
mitochondria, muscles from three rats were pooled for each
of five independent experiments in lean and obese rats.
Preparation of subsarcolemmal and intermyofibrillar mito-
chondria, and palmitate oxidation in these mitochondria
were performed as described [3, 24].
Statistics
Correlations were performed using least squares linear
regression. Two factor (lean vs obese) repeated measures
(transfected vs control muscle) analyses of variance were
used to compare the variables under investigation. All data
are reported as mean ± SEM.
Results
Comparison of selected metabolic indices in lean and obese
Zucker rats
Circulating fatty acid (lean 0.33±0.06 mmol/l, obese 0.81±
0.12 mmol/l) and insulin (lean 1.8±0.5 ng/ml, obese 8.3±
1.3 ng/ml) levels were greater in obese rats (p<0.05).
Glucose concentrations were comparable in both groups
(lean 10.5±1.2 mmol/l, obese 11.8±1.5 mmol/l).
The proportion of oxidative muscle fibres was greater in
selected muscles (EDL, PL, WG) of obese rats than in lean
animals (Table 1). In both groups, PGC-1α correlated
highly (r ≥ 0.88) with the proportion of oxidative fibres,
glucose (GLUT4) and fatty acid transporters (FAT, fatty
acid binding protein [FABP]pm), and COXIV (Fig. 1a–f),
but not with AMPKα2 or selected insulin-signalling
proteins (IRS1, PI3-kinase, Akt2), which were reduced by
20 to 45% in obese Zucker rats (Fig. 1a).
Modest PGC-1α overproduction increases mitochondrial
density
Pgc-1α was transfected into the tibialis anterior muscle in
one hindlimb, while the contralateral muscle served as
control (empty vector). Transfection increased Pgc-1α
mRNA (lean by 31%, obese by 37%; Fig. 2a) and protein
(lean by 20%, obese by 27%; Fig. 2b). This modest PGC-
1α increase induced mitochondrial biogenesis, as shown by
the increases in mitochondrial DNA (lean 55%, obese 44%
higher; Fig. 2c) and citrate synthase activity (lean 21%,
obese 20% higher; Fig. 2d). PGC-β protein levels were not
different in lean and obese animals, nor were they altered
by Pgc-1α transfection (data not shown)
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Glucose transport, GLUT4 and insulin signalling proteins
Lean and obese control muscles (empty vector) Insulin-
stimulated, but not basal rates of glucose transport were
lower in obese rats (Fig. 3a, b). Protein levels of GLUT4
(Fig. 3d) and AS160 (Fig. 3f) were similar in lean and
obese Zucker rat muscles, but Akt2 protein was reduced in
obese animals (−60%; Fig. 3e). Basal phosphorylation of
Akt and AS160 did not differ in lean and obese animals
(data not shown). However, insulin-stimulated phosphory-
lation of insulin signalling proteins was reduced in muscles
of obese rats (Akt thr308 −82% [Fig. 3e] and ser473 –71%
[data not shown]; AS160 thr642 –45% [Fig. 3f]; p<0.05).
Lean and obese Pgc-1α-transfected muscles Pgc-1α trans-
fection increased the insulin-stimulated, but not basal
(Fig. 3a) rates of glucose transport in lean (19%) and obese
(21%) rat muscles (p<0.05; Fig. 3b). The absolute increase
in Pgc-1α-transfected muscle was 60% smaller in the obese
rats compared with lean rats (Fig. 3c).
PGC-1α also induced an increase in GLUT4 (lean 13%,
obese 27%; Fig. 3d), but not in Akt2 and AS160 protein
levels (Fig. 3e, f). However, Pgc-1α transfection did
increase the insulin-stimulated phosphorylation of Akt
thr308 (lean 47%, obese 44%; Fig. 3e) and ser473 (lean
29%, obese 24%, data not shown), although in obese
animals Akt phosphorylation remained lower (Fig. 3f).
Relatively greater improvements in insulin-stimulated
AS160 phosphorylation (thr642) occurred in obese (45%)
compared with lean (18%) animals. Hence, AS160 phos-
phorylation was restored to 80% of that in lean control
muscle (Fig. 3f).
Intramuscular lipids, FAT and both subsarcolemmal
and intermyofibrillar mitochondrial fatty acid oxidation
Lean and obese control muscles (empty vector) Intramus-
cular triacylglycerol, diacylglycerol and ceramide concen-
trations were greater in the obese animals (Fig. 4a–c). FAT
protein levels did not differ between groups (Fig. 4d). In lean
rats, the rate of palmitate oxidation by subsarcolemmal mito-
chondria was 27% lower than that by intermyofibrillar
mitochondria. In obese rats, by contrast, subsarcolemmal
mitochondrial palmitate oxidation was upregulated (by 56%)
and was similar to the rate of intermyofibrillar mitochondrial
palmitate oxidation (Fig. 4e, f).
Lean and obese Pgc-1α-transfected muscles Increases in
PGC-1α protein decreased intramuscular triacylglycerol
content in obese animals (−60%) but increased it in lean
animals (+31%; Fig. 4a). Intramuscular diacylglycerol
(−20%) and ceramide content (−28%) were reduced in
obese Zucker rat muscle only (Fig. 4b, c). In both groups,
PGC-1α protein increased FAT protein levels in muscle
(lean +25%, obese +16%; Fig. 4d).
Table 1 Muscle fibre composition of hindlimb muscles in lean and obese Zucker rats
Muscle fibre type per group Skeletal muscles
EDL RTA WTA SOL PL RG WG
Oxidative (%SO+%FOG)a
Lean 42.3±3.9 68.6±1.4 25.0±4.4 100 42.2±5.5 93.3±2.9 7.1±2.3
Obese 58.5±3.6* 70.0±0.3 15.9±1.9* 100±1.9 72.3±2.3* 94.3±2.5 27.3±5.8*
SO (%)
Lean 2.2±0.4 6.5±0.3 0 74.8±2.4 2.8±0.5 38.1±4.7 0
Obese 2.4±0.8 4.1±1.1 0 67.6±2.6 9.0±0.7* 31.4±4.7 0
FOG (%)
Lean 40.1±3.5 62.1±1.6 25.0±4.4 25.5±2.6 39.3±5.4 55.1±2.4 7.1±5.1
Obese 56.1±2.9* 65.9±1.1 15.9±1.9 32.2±0.3 63.8±2.4* 62.9±2.3 27.3±5.8*
FG (%)
Lean 57.7±3.9 31.2±1.6 75.0±4.4 0 57.8±5.5 6.7±2.8 93.1±2.2
Obese 43.5±5.2* 30.1±0.3 84.1±1.9* 0 27.3±2.2* 5.7±2.5 72.7±6.0*
Values are mean ± SEM, n=5 lean and n=5 obese Zucker rats
*p<0.05 for obese vs lean
FG, fast-twitch glycolytic muscle fibre content of each muscle; RG, red gastrocnemius; RTA, red tibialis anterior; SOL, soleus; WTA, white
tibialis anterior
a Oxidative muscle fibre composition was based on summing the fast-twitch oxidative glycolytic (FOG) and slow-twitch oxidative (SO) muscle fibre
content of each muscle
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PGC-1α selectively targeted subsarcolemmal mitochon-
dria, as palmitate oxidation was increased in this subgroup
of mitochondria (lean +37% and obese +18%) relative to
the contralateral control muscles (Fig. 4d). PGC-1α did not
alter intermyofibrillar mitochondrial palmitate oxidation
either in lean or in obese Zucker rat muscles (Fig. 4e).
Discussion
We have shown for the first time that a modest increase in
PGC-1α levels increases mitochondrial biogenesis and
improves both lipid metabolism and insulin-stimulated
glucose transport in insulin-resistant muscle of obese Zucker
rats in vivo. These changes occurred in concert with targeted
improvement of fatty acid oxidation in subsarcolemmal
mitochondria and increases in GLUT4 protein and in insulin-
stimulated phosphorylation of insulin signalling proteins
(Akt, AS160). The intramuscular lipid reduction induced by
PGC-1α was greater in obese Zucker rats, while the increase
in insulin-stimulated glucose transport that was induced by
PGC-1α was greater in the lean animals.
Characterisation of lean and obese Zucker rats
The obese Zucker rats studied exhibited the expected
characteristics, including: (1) increased circulating concen-
trations of fatty acids and insulin, with comparable levels of
glucose; (2) impairment of insulin-stimulated glucose




















































































































































































Fig. 1 Relationship of PGCα protein with muscle fibre composition
and with selected metabolic proteins in metabolically heterogenous
skeletal muscles in lean and obese Zucker rats. Oxidative muscle fibre
composition was determined as previously reported [3], i.e. the sum of
slow oxidative muscle+fast-twitch oxidative muscle fibres. a Western
blots of PGC-1α and proteins involved in glucose transport, insulin
signalling, fatty acid transport, fuel utilisation and an index of
mitochondrial density. Lanes: 1, EDL; 2, red TA (RTA); 3, white TA
(WTA); 4, soleus (SOL); 5, plantaris (PL); 6, red gastrocnemius (RG);
7, white gastrocnemius (WG). b Muscle fibre composition in lean (L)
and obese (O) rat muscles. White bars, fast-twitch glycolytic muscle
fibres; hatched bars, oxidative muscle fibres (fast-twitch oxidative
glycolytic fibers+slow-twitch oxidative fibers). c Relationship be-
tween muscle fibre composition and PGC-1α protein levels in lean (L)
and obese (O) rats (r=0.96 in lean; r=0.92 in obese). The relationship
of PGC-1α protein with (d) indices of mitochondrial density (COXIV)
(r=0.88), (e) glucose transport (GLUT4) (r=0.87) and (f) fatty acid
transport, i.e. FAT (r=0.96), and (g) FABPpm (r=0.89) White circles,
lean; black circles, obese. Data are shown as mean ± SEM and are
based on muscles from four to six animals
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phosphorylation [27, 28]; and (4) increased concentration
of intramuscular triacylglycerol [14, 25, 26]. The latter
presumably reflects an attempt to limit intramuscular muscle
lipotoxicity, as this lipid depot is increased in insulin-
sensitive athletes (the athlete paradox) [2] and triacylglycerol
provides a cytoprotective role in lipid overload states [29].
As in healthy animals [3, 30], we found that a smaller
than twofold range of PGC-1α protein levels is highly related
to the oxidative and substrate transport capacities among
metabolically heterogeneous muscles in lean and obese
Zucker rats. The correlations between PGC-1α and rodent
muscle oxidative capacity, and between PGC-1α and both
GLUT4 and FAT support the idea that in lean and obese
muscles PGC-1α is central to a coordinated metabolic
programme that upregulates a number of genes simul-
taneously to produce an oxidative muscle phenotype that
relies extensively on blood-borne substrates for energy
provision [3, 5, 31]. The small range of PGC-1α protein
abundance across a range of heterogeneous muscles implies
that small, physiologically induced changes in PGC-1α
protein [6, 30, 32, 33] can have pronounced effects on
muscle metabolism, as shown by the present study and
others [3, 16].
Overexpression of Pgc-1α in skeletal muscle of lean
and obese Zucker rats
To upregulate PGC-1α protein in muscle, we used an
electrotransfection procedure, as we [3, 16, 17, 21, 34] and
others [4, 20, 35] have done previously for different genes.
Muscle transfection efficiencies are typically maintained
within a 30% to 40% range, as was done in the present
study and others [3, 4, 16, 17, 20, 34, 35]. A greater
transfection efficiency requires higher electroporation vol-
tages, which induce muscle damage (C. R. Benton and A.
Bonen, unpublished data) [20]. Compared with transgenic
Pgc-1α animals, transfection of a single muscle with Pgc-
1α offers several advantages: (1) it is possible to examine
PGC-1α-induced metabolic regulation in a controlled
manner, in vivo; (2) this can be done without disturbing
whole-body fuel homeostasis; (3) the animal serves as its
own control; and (4) the resulting phenotype is not unusual,
as is the case in Pgc-1α transgenic mice [10, 11, 36].
It is well known that only a select number of muscle
fibres can ‘drive’ the metabolic changes observed within
the whole muscle. Indeed, much of our understanding of
the adaptive capacities in muscle (e.g. enzyme activities,
glucose transport, gene expression and transcription rates,
etc.) is based on studies in which only some of the muscle
fibres have been affected during exercise (i.e. the motor
unit size recruitment principle). Yet, large changes within
only some muscle fibres, whether induced by exercise [37]
or electrotransfection as in the present study and others [3, 4],
permit us to observe meaningful metabolic adaptations
within the whole muscle (i.e. an average effect across all
muscle fibres). Based on our transfection efficiency, we
estimate that PGC-1α is upregulated by 60 to 75% in the
transfected muscle fibres, an effect that is within a
physiologically meaningful range [30, 38]. Importantly, this
yields metabolically meaningful changes in whole-muscle
mitochondrial biogenesis, protein levels, insulin sensitivity
and lipid metabolism, as seen in the present study and others
[3, 16].
Modest PGC-1α protein increases improve insulin
signalling and sensitivity
Modest PGC-1α protein increases induced improvements
























































































































Fig. 2 Effects of Pgc-1α transfection on Pgc-1α mRNA and protein,
and on indices of mitochondrial density in lean and obese Zucker rat
muscle. a Pgc-1α mRNA, (b) PGC-1α protein as blot and bar graph,
(c) mitochondrial DNA and (d) citrate synthase activity in PGC-1α-
transfected (black bars) and contralateral control (white bars) muscles.
b Equal protein concentrations were loaded for each muscle. Data are
shown as mean ± SEM and were compared using paired analyses
within each group and unpaired analyses between groups, n=4–5 for
each muscle. *p<0.05 for comparisons indicated with the brackets
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including increases in GLUT4 levels and in insulin-
stimulated Akt and AS160 phosphorylation, without any
concurrent changes in Akt and AS160 protein levels. Given
that insulin-stimulated AS160 phosphorylation was almost
fully restored to normal in the Pgc-1α-transfected muscles,
it was surprising that the extent of PGC-1α-induced
improvement in insulin-stimulated glucose transport was
smaller in insulin-resistant than in lean muscles. Other
studies have shown that insulin-stimulated AS160 phos-
phorylation is highly correlated with muscle insulin sensi-
tivity [39] and its restoration in insulin-resistant muscle
[40]. Presumably, with Pgc-1α transfection, other GLUT4
signalling/trafficking processes were not sufficiently altered
to fully normalise insulin-stimulated glucose transport in
insulin-resistant muscles, despite almost full restoration of
AS160 phosphorylation.
The basis for the PGC-1α-induced improvement in
insulin-stimulated phosphorylation of signalling proteins
in skeletal muscle in this and other studies [3, 41, 42] is
unknown. It is tempting to speculate that these increases
resulted from the reductions in intramuscular lipids [1].
Others have speculated that the unexpected increase in
intramuscular lipids in muscles of Pgc-1α transgenic mice
accounted for the resulting impairment of insulin-stimulated
Akt2 activity and glucose transport [11]. However, some
caution is required, as changes in intramuscular lipids are
not always associated with changes in insulin-stimulated
phosphorylation of signalling proteins [28, 40].
The improvements (∼20%) in insulin-stimulated glucose
transport in muscles of lean and insulin-resistant obese rats
were within the range (%) observed with other therapeutic
interventions, i.e. either exercise training in lean or obese
animals [43], or rosiglitazone treatment [44, 45]. However,
these changes were observed after many weeks of treat-
ment, whereas Pgc-1α transfection induced changes within
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Fig. 3 Effects of a modest increase in PGC-1α protein on insulin
sensitivity, the glucose transporter GLUT4 and insulin signalling
proteins in lean and obese Zucker rat muscles. a Basal and insulin-
stimulated glucose transport in perfused hindlimb muscles, as (b)
relative changes (%=100×transfected/control) and (c) absolute
changes in insulin-stimulated glucose transport in Pgc-1α-transfected
muscles (Δ, transfected-control). d GLUT4 protein levels, (e) Akt2
levels and insulin-stimulated Akt thr308 phosphorylation, and (f)
AS160 protein levels and insulin-stimulated AS160 thr642 phosphor-
ylation. d–f Equal protein concentrations were loaded for each muscle.
White bars, control (muscles transfected with empty vector); black
bars, Pgc-1α transfected muscles. Data are shown as mean ± SEM and
were compared using paired analyses within each group and unpaired
analyses between groups, n=6–7 control and transfected muscles. *p<
0.05 for transfected vs control; †p<0.05 for obese muscles (control
and transfected) vs lean muscles (control and transfected)
Diabetologia (2010) 53:2008–2019 2015
a 20% to 25% increase in insulin-stimulated glucose transport
after 7 to 14 days, either when PGC-1α [3] or carnitine
palmitoyltransferase 1 (CPTI) [4] were overproduced in
healthy animals [3] or in diet-induced, insulin-resistant
animals [4]. Thus, a modest PGC-1α protein increase
improves insulin sensitivity rapidly within ranges observed
in other experimental models. We recognise that PGC-1α
did not fully normalise insulin sensitivity. This was also
observed in insulin-resistant, CPTI-transfected muscles [4].
However, other than studies in cell lines [7], our work is the
first to show that modest PGC-1α overexpression improves
insulin sensitivity in vivo in healthy (as shown by the present
and another study [3]) and in insulin-resistant muscle
(present study).
FAT, intramuscular lipids and mitochondrial
palmitate oxidation
FAT is a key fatty acid transporter. The plasmalemmal
content of this protein is correlated with intramuscular
lipid accumulation in obesity and type 2 diabetes [46].
A large muscle-specific increase in Pgc-1α (mRNA
increased by 600%) provoked diet-induced insulin resis-
tance, which was attributed to a large increase in Fat (also
known as Cd36) (mRNA increased by 300%) and the
consequent increases in intramuscular diacylglycerol and
long-chain fatty acyl CoAs [11]. In contrast, when we
modestly overexpressed Pgc-1α (∼25%), insulin sensitiv-
ity was improved, as seen in the present and another study
[3]. A key reason is that this limited the extent of PGC-1α-
mediated FAT upregulation. While a large increase in FAT
contributes to intramuscular lipid accumulation [11], a
small increase in muscle FAT is not deleterious, as this
increases fatty acid oxidation only [34]. Thus to improve
insulin sensitivity in muscle via PGC-1α, it is essential, as
we have previously suggested [3, 13], to limit the increase
in PGC-1α protein in order to limit the upregulation of
FAT protein.
It is not clear why intramuscular diacylglycerol and







































































































































































Fig. 4 Effects of a modest increase in PGC-1α protein on the fatty
acid transporter FAT, intramuscular lipids accumulation and mito-
chondrial fatty acid oxidation in lean and obese Zucker rat muscles. a
Triacylglycerol, (b) diacylglycerol, (c) ceramide, (d) FAT protein and
(e) palmitate oxidation in isolated subsarcolemmal and (f) intermyofi-
brillar mitochondria. a–c Five muscles and (e, f) three muscles were
pooled for each of 6–7 independent determinations. d Equal protein
concentrations were loaded for each muscle. White bars, control
(muscles transfected with empty vector); black bars, PGC-1α-trans-
fected muscles. Data are shown as mean ± SEM and were compared
using paired analyses within each group and unpaired analyses
between groups. *p<0.05 for comparisons indicated with the brackets
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Nevertheless, these reductions may have contributed to the
improved insulin-stimulated phosphorylation of insulin
signalling proteins (Akt, AS160) in the obese animals.
However, a similar rationale cannot be used for lean animals
or in CPTI transfected muscles in chow-fed animals [4], as
in these animals intramuscular lipid metabolites were not
reduced. Recent data indicate that changes in insulin-
stimulated phosphorylation of signalling proteins can occur
independently of changes in intracellular lipids [28],
including restoration of muscle insulin sensitivity [40].
Thus, while PGC-1α-mediated reductions in intramuscular
lipids may have contributed to improved insulin-stimulated
phosphorylation of Akt and AS160 in obese animals, this is
less certain for the lean animals.
It is known that subsarcolemmal mitochondria are
more malleable than intermyofibrillar mitochondria.
With changes in aerobic fitness induced via exercise
training or inactivity [47, 48], as well as in obesity and
type 2 diabetes [9, 49], changes in mitochondrial function
and density are largely confined to subsarcolemmal mito-
chondria [47–49]. Although the bases for selective changes
in subsarcolemmal mitochondria are not known, our work,
i.e. the present and previous studies [3, 24], indicates that
PGC-1α targets subsarcolemmal mitochondria. The PGC-
1α-mediated upregulation of subsarcolemmal fatty acid
oxidation was not attributable to concurrent changes in
CPTI (data not shown; [3]). PGC-1α targeting of subsarco-
lemmal mitochondria may be an attempt to efficiently
remove, via β-oxidation, fatty acids as soon as they cross
the sarcolemma, thus minimising their intramuscular accu-
mulation. However, the relationship between skeletal muscle
fatty acid oxidation and intramuscular lipid accumulation is
not necessarily a simple reciprocal one [14, 50], as has been
widely thought.
Insulin sensitivity depends on the level of PGC-1α
overproduction
The effects of Pgc-1α overexpression on insulin sensitivity
in vivo can be strikingly different. When Pgc-1α over-
expression is maintained within a low range (<100%),
improvements in insulin sensitivity are observed (Fig. 5),
but when muscle-specific Pgc-1α overexpression is induced
far beyond normal physiological limits, insulin-stimulated
glucose disposal is reduced (Fig. 5). These different PGC-
1α-mediated responses in insulin sensitivity are likely to be
related to differences in the PGC-1α-induced increases in
FAT levels (see above).
Exercise and PGC-1α
Our work in the present and a previous study [3] showing
that modest PGC-1α overproduction is sufficient to
improve lipid metabolism and insulin action evolved from
observations that exercise training-induced upregulation of
insulin sensitivity is accompanied by a modest PGC-1α
increase. While it may be desirable to seek a pharmaco-
logical means to upregulate PGC-1α, it is difficult to ignore
the fact that the simplest way to upregulate PGC-1α is via
exercise.
Summary
By increasing PGC-1α protein only modestly, an approach
based on physiological and metabolic considerations, we
found that insulin-stimulated glucose transport was improved
in healthy and insulin-resistant skeletal muscle. The under-
lying mechanisms appear to be: (1) PGC-1α-induced
increases in GLUT4 protein levels; (2) improvements in lipid





























Fig. 5 Comparison between relative changes in Pgc-1α overexpres-
sion (%) and changes in insulin-stimulated glucose utilisation (%) in
healthy animals. Data are from the present study and recently
published studies [3, 10, 11, 41] in which Pgc-1α was overexpressed
to varying levels in transgenic animals [10, 11, 41] or in electro-
transfected muscles (as here and in a previous study [3]). Pgc-1α
mRNA increase (%) was calculated relative to controls in the studies
mentioned. Insulin-stimulated glucose utilisation in the various studies
was based on various methods [3, 10, 11, 41] and therefore the
increase (%) was calculated relative to controls. White circles, relative
increase (%) in obese Zucker rats in the present study (these data were
not include in the derived regression line). These data suggest that
when Pgc-1α mRNA level is maintained continuously at a high level
(i.e. >100% increase), insulin-stimulated glucose utilisation deterio-
rates sufficiently to result in insulin resistance (grey box). In contrast,
maintaining Pgc-1α mRNA expression more modestly (<100%)
increases insulin sensitivity (clear box). These contrasting responses
may reflect, in part, the differential effects of PGC-1α protein
(depending on its increase) on FAT-mediated intramuscular lipid
accumulation, which can interfere with insulin signalling (see the
Discussion)
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metabolism and insulin-stimulated phosphorylation of insulin
signalling proteins; and (3) limitation of PGC-1α-induced
increase in FAT. In obese muscles, the improved insulin-
stimulated glucose transport and insulin signalling were less
robust, while improvements in lipid metabolism were greater.
Nevertheless, our work demonstrates for the first time the
therapeutic potential of PGC-1α for improving insulin action
in insulin-resistant skeletal muscle.
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